Immunovaccine to Present at 19th Annual Rodman & Renshaw Global Investment Conference
August 30 2017 - 7:05AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced it will present at
the 19th Annual Rodman & Renshaw Global Investment Conference
set for September 10-12 at the Lotte New York Palace Hotel in New
York, New York.
Chief Executive Officer Frederic Ors is scheduled to
present an overview of the Company’s recent progress and future
strategy on Tuesday, September 12, at 10:00 a.m. ET in the Holmes
II meeting room of the hotel. To arrange a meeting with management,
please contact Anna Fryday at AFryday@imvaccine.com.
The presentation will be available on Immunovaccine’s website at
www.imvaccine.com following the meeting.
About ImmunovaccineImmunovaccine Inc. is a
clinical-stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious
diseases. Immunovaccine develops T cell-activating cancer
immunotherapies and other vaccine candidates based on DepoVax™, the
Company’s patented platform that provides controlled and prolonged
exposure of antigens and adjuvant to the immune system.
Immunovaccine has advanced two T cell activation therapies for
cancer through Phase 1 human clinical trials and is currently
conducting a Phase 1b study with Incyte Corporation assessing lead
cancer therapy, DPX-Survivac, as a combination therapy in ovarian
cancer. The Company is also exploring additional applications of
DepoVax™, including DPX-RSV, an innovative vaccine candidate for
respiratory syncytial virus (RSV), which has recently completed a
Phase 1 clinical trial. Immunovaccine also has ongoing clinical
projects to assess the potential of DepoVax™ to address malaria and
the Zika virus. Connect at www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA
Mike Beyer, Sam Brown Inc.
T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS
Pierre Labbé, Chief Financial Officer
T: (902) 492-1819 E: info@imvaccine.com
Patti Bank, Managing Director, Westwicke Partners
O: (415) 513-1284
T: (415) 515-4572 E: patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024